التفاصيل البيبلوغرافية
| العنوان: |
Targeting BRD4 attenuates the stemness and aggressiveness of ameloblastoma. |
| المؤلفون: |
Xie, Jiaxiang, Zhang, Jingqi, Xiong, Gan, Ouyang, Shengqi, Yun, Bokai, Xu, Xiuyun, Wang, Wenjin, Zhang, Ming, Xie, Nan, Chen, Demeng, Wang, Cheng |
| المصدر: |
Oral Diseases; Jul2024, Vol. 30 Issue 5, p3212-3224, 13p |
| مصطلحات موضوعية: |
CELL migration, PEARSON correlation (Statistics), BROMODOMAIN-containing proteins, PHENOMENOLOGICAL biology, T-test (Statistics), RESEARCH funding, BIOCHEMISTRY, GENE expression, IMMUNOHISTOCHEMISTRY, RNA, BIOINFORMATICS, MICROBIOLOGICAL assay, DRUG efficacy, ANALYSIS of variance, ONE-way analysis of variance, STEM cells, CARCINOGENESIS, AMELOBLASTOMA, SEQUENCE analysis, DISEASE progression, WNT proteins, EVALUATION |
| مستخلص: |
Background: BRD4, belonging to the bromodomain extra‐terminal (BET) protein family, plays a unique role in tumor progression. However, the potential impact of BRD4 in ameloblastoma (AM) remains largely unknown. Herein, we aimed to assess the expression and functional role of BRD4 in AM. Methods: The expression level of BRD4 was assessed by immunohistochemistry. The proliferation, migration, invasion, and tumorigenic abilities of AM cells were assessed by a series of assays. To explore the molecular expression profile of BRD4‐depleted AM cells, RNA sequencing (RNA‐seq) was performed. Bioinformatic analysis was performed on AM expression matrices obtained from the Gene Expression Omnibus (GEO). The therapeutic efficacy of BET‐inhibitors (BETi) was assessed with AM patient‐derived organoids. Results: Upregulation of BRD4 was observed in conventional AMs, recurrent AMs, and ameloblastic carcinomas. Depletion of BRD4 inhibited proliferation, invasion, migration, and tumorigenesis in AM. Administration of BETi attenuated the aggressiveness of AM and the growth of AM patient‐derived organoids. Bioinformatic analysis indicated that BRD4 may promote AM progression by regulating the Wnt pathway and stemness‐associated pathways. Conclusion: BRD4 increases the aggressiveness and promotes the recurrence of ameloblastoma by regulating the Wnt pathway and stemness‐associated pathways. These findings highlight BRD4 as a promising therapeutic target in AM management. [ABSTRACT FROM AUTHOR] |
|
Copyright of Oral Diseases is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder